Clinical use of positron emission tomography in the management of cutaneous melanoma

Kent P. Friedman, Richard L. Wahl

Research output: Contribution to journalArticle

Abstract

Cutaneous melanoma is the seventh most common newly diagnosed cancer among Americans. It frequently metastasizes and is difficult to treat. Accurate disease staging is important for optimizing therapy and selecting appropriate patients for experimental trials. Positron emission computed tomography (PET) using 18F-fluorodeoxyglucose (FDG) has been studied extensively since 1991 and shows great promise in the detection of metastatic cutaneous melanoma. Cumulative data from the last 13 years is reviewed in this article and suggest that FDG-PET is the modality of choice for evaluating patients who fit into one of four categories: 1) individuals with a high risk for distant metastases based on extent of locoregional disease, 2) patients with findings that are suspicious for distant metastases, 3) individuals with known distant tumor deposits who still stand to benefit from customized therapies if new lesions are discovered or treated lesions regress, and 4) patients at high risk for systemic relapse who are considering aggressive medical therapy. Despite the overall superiority of FDG-PET in the detection of melanoma metastases, limitations exist with respect to detection of small lung nodules and brain metastases, which are better evaluated by computed tomography and magnetic resonance imaging, respectively.

Original languageEnglish (US)
Pages (from-to)242-253
Number of pages12
JournalSeminars in Nuclear Medicine
Volume34
Issue number4
DOIs
StatePublished - Oct 2004

Fingerprint

Emission-Computed Tomography
Positron-Emission Tomography
Melanoma
Neoplasm Metastasis
Skin
Fluorodeoxyglucose F18
Neoplasms
Therapeutics
Tomography
Magnetic Resonance Imaging
Recurrence
Lung
Brain

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Clinical use of positron emission tomography in the management of cutaneous melanoma. / Friedman, Kent P.; Wahl, Richard L.

In: Seminars in Nuclear Medicine, Vol. 34, No. 4, 10.2004, p. 242-253.

Research output: Contribution to journalArticle

Friedman, Kent P. ; Wahl, Richard L. / Clinical use of positron emission tomography in the management of cutaneous melanoma. In: Seminars in Nuclear Medicine. 2004 ; Vol. 34, No. 4. pp. 242-253.
@article{c96b0cdc92284a82aec0cdd6bee72567,
title = "Clinical use of positron emission tomography in the management of cutaneous melanoma",
abstract = "Cutaneous melanoma is the seventh most common newly diagnosed cancer among Americans. It frequently metastasizes and is difficult to treat. Accurate disease staging is important for optimizing therapy and selecting appropriate patients for experimental trials. Positron emission computed tomography (PET) using 18F-fluorodeoxyglucose (FDG) has been studied extensively since 1991 and shows great promise in the detection of metastatic cutaneous melanoma. Cumulative data from the last 13 years is reviewed in this article and suggest that FDG-PET is the modality of choice for evaluating patients who fit into one of four categories: 1) individuals with a high risk for distant metastases based on extent of locoregional disease, 2) patients with findings that are suspicious for distant metastases, 3) individuals with known distant tumor deposits who still stand to benefit from customized therapies if new lesions are discovered or treated lesions regress, and 4) patients at high risk for systemic relapse who are considering aggressive medical therapy. Despite the overall superiority of FDG-PET in the detection of melanoma metastases, limitations exist with respect to detection of small lung nodules and brain metastases, which are better evaluated by computed tomography and magnetic resonance imaging, respectively.",
author = "Friedman, {Kent P.} and Wahl, {Richard L.}",
year = "2004",
month = "10",
doi = "10.1053/j.semnuclmed.2004.06.001",
language = "English (US)",
volume = "34",
pages = "242--253",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Clinical use of positron emission tomography in the management of cutaneous melanoma

AU - Friedman, Kent P.

AU - Wahl, Richard L.

PY - 2004/10

Y1 - 2004/10

N2 - Cutaneous melanoma is the seventh most common newly diagnosed cancer among Americans. It frequently metastasizes and is difficult to treat. Accurate disease staging is important for optimizing therapy and selecting appropriate patients for experimental trials. Positron emission computed tomography (PET) using 18F-fluorodeoxyglucose (FDG) has been studied extensively since 1991 and shows great promise in the detection of metastatic cutaneous melanoma. Cumulative data from the last 13 years is reviewed in this article and suggest that FDG-PET is the modality of choice for evaluating patients who fit into one of four categories: 1) individuals with a high risk for distant metastases based on extent of locoregional disease, 2) patients with findings that are suspicious for distant metastases, 3) individuals with known distant tumor deposits who still stand to benefit from customized therapies if new lesions are discovered or treated lesions regress, and 4) patients at high risk for systemic relapse who are considering aggressive medical therapy. Despite the overall superiority of FDG-PET in the detection of melanoma metastases, limitations exist with respect to detection of small lung nodules and brain metastases, which are better evaluated by computed tomography and magnetic resonance imaging, respectively.

AB - Cutaneous melanoma is the seventh most common newly diagnosed cancer among Americans. It frequently metastasizes and is difficult to treat. Accurate disease staging is important for optimizing therapy and selecting appropriate patients for experimental trials. Positron emission computed tomography (PET) using 18F-fluorodeoxyglucose (FDG) has been studied extensively since 1991 and shows great promise in the detection of metastatic cutaneous melanoma. Cumulative data from the last 13 years is reviewed in this article and suggest that FDG-PET is the modality of choice for evaluating patients who fit into one of four categories: 1) individuals with a high risk for distant metastases based on extent of locoregional disease, 2) patients with findings that are suspicious for distant metastases, 3) individuals with known distant tumor deposits who still stand to benefit from customized therapies if new lesions are discovered or treated lesions regress, and 4) patients at high risk for systemic relapse who are considering aggressive medical therapy. Despite the overall superiority of FDG-PET in the detection of melanoma metastases, limitations exist with respect to detection of small lung nodules and brain metastases, which are better evaluated by computed tomography and magnetic resonance imaging, respectively.

UR - http://www.scopus.com/inward/record.url?scp=5444233079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5444233079&partnerID=8YFLogxK

U2 - 10.1053/j.semnuclmed.2004.06.001

DO - 10.1053/j.semnuclmed.2004.06.001

M3 - Article

C2 - 15493002

AN - SCOPUS:5444233079

VL - 34

SP - 242

EP - 253

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 4

ER -